Genexine (XKRX:095700) Change In Other Working Capital : ₩2,366 Mil (TTM As of Mar. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Genexine Change In Other Working Capital?

Genexine's Change In Other Working Capital for the quarter that ended in Mar. 2024 was ₩-5,469 Mil. It means Genexine's Other Working Capital declined by ₩5,469 Mil from Dec. 2023 to Mar. 2024 .

Genexine's Change In Other Working Capital for the fiscal year that ended in Dec. 2023 was ₩5,751 Mil. It means Genexine's Other Working Capital increased by ₩5,751 Mil from Dec. 2022 to Dec. 2023 .

Genexine Change In Other Working Capital Historical Data

The historical data trend for Genexine's Change In Other Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genexine Change In Other Working Capital Chart

Genexine Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Other Working Capital

Get a 7-Day Free Trial

-5,083.12

8,215.40

-1,969.11

-8,053.74

5,750.63

Genexine Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Other Working Capital	Get a 7-Day Free Trial															-2,084.21	-5,990.32	9,583.77	4,241.39	-5,468.52

Genexine Change In Other Working Capital Calculation

Change In Other Working Capital is any increase or decrease between periods of other working capital that are not otherwise classified.

Change In Other Working Capital for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩2,366 Mil.

Genexine Change In Other Working Capital Related Terms

Thank you for viewing the detailed overview of Genexine's Change In Other Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Genexine (XKRX:095700) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genexine Inc (XKRX:095700) » Definitions » Change In Other Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

700 Daewangpangyo-ro, Gyeonggi-do, Korea Bio Park Building B, Bundang-gu, Seongnam-si, KOR, 13488

Website

http://www.genexine.com

Genexine Inc is a clinical-stage biotechnology company. It is focused on the development and commercialization of immunotherapeutics and next-generation long-acting biologics. Its primary technologies are Therapeutic DNA vaccine technology and Hyfc platform. The company's product pipeline includes products such as GX-H9, GX-E2, GX-G3, GX-G6, and Papitrol-188 among others.

Genexine (XKRX:095700) Headlines

No Headlines